Israel Kanaan Blaas

Dr. Israel Kanaan Blaas

Neuroscience, Faculdade de Medicina do ABC, Santo André, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MMMatheus Cheibub David Marin
Matheus Cheibub David Marin
Maria Olivia Pozzolo PedroMaria Olivia Pozzolo Pedro
Maria Olivia Pozzolo Pedro
GPGiuliana Perrotte
Giuliana Perrotte
Anderson Sousa Martins-da-SilvaAnderson Sousa Martins-da-Silva
Anderson Sousa Martins-da-Silva
DLDângela Layne Silva Lassi
Dângela Layne Silva Lassi
JCJoão Mauricio Castaldelli-Maia
João Mauricio Castaldelli-Maia
(1) Background: The treatment of substance addiction is challenging and has persisted for decades, with only a few therapeutic options. Although there are some recommendations for specific treatments for Alcohol Use Disorder (AUD), there is no specific medication used to treat alcohol cravings, which could benefit millions of patients that are suffering from alcoholism. Cravings, or the urge to use drugs, refer to the desire to experience the effects of a previously experienced psychoactive substance. (2) Methods: We included original studies of alcohol abuse or dependence extracted from a controlled, blind, pharmacological treatment study which presented measures and outcomes related to alcohol cravings. (3) Results: Specific drugs used for the treatment of alcoholism, such as Naltrexone and Acamprosate, have had the best results in relieving craving symptoms, as well as promoting abstinence. Baclofen and anticonvulsants such as Gabapentin and Topiramate have shown good results in promoting abstinence and the cessation of cravings. (4) Conclusions: Specific drugs used for the treatment of alcoholism to obtain the best results can be considered the gold standard for promoting abstinence and relieving cravings. Anticonvulsants and Baclofen also had good results, with these medications being considered as second-line ones. Varenicline is an option for alcohol dependents who also concomitantly ingest tobacco.

19 May 2022 in International Review of Psychiatry
Verified
Journal Article
Closed access
AAAna Beatriz Balieiro Abrahão
Ana Beatriz Balieiro Abrahão
Guilherme KortasGuilherme Kortas
Guilherme Kortas
IBIsrael Kanaan Blaas
Israel Kanaan Blaas
GGGislaine Koch Gimenes
Gislaine Koch Gimenes
KLKae Leopoldo
Kae Leopoldo
JCJoão Mauricio Castaldelli-Maia
João Mauricio Castaldelli-Maia
This paper aimed to review the literature regarding the impact of discrimination on substance use disorders among Sexual Minorities (SM), with a focus on alcohol, opioids, stimulants, polydrug use, chemsex, cannabis and tobacco, as well as inequalities in the access to health care services. It is alarmingly clear that SM report higher rates of morbidity if compared to the general population. Health care delivery inequalities have also been reported in this special population. Also, the lack of data from low- and middle-income countries on substance use among SM is a major concern. Certainly, discrimination play a key-role among leading factors to substance abuse, continued use, disorders, and lower levels of preventive and treatment interventions. However, it may be difficult to estimate the impact of discrimination because of the lack of research data and different methodologies of literature studies. Moreover, SM are differently categorized and defined and evidences may be not comparable between studies. There is an urgent need of strategic guidelines and research investments aimed at prioritizing these populations disproportionately impacted by substance use. Equity-oriented policies and programs can facilitate opportunities and decrease substance use in these vulnerable subgroups, including community- and peer-led initiatives and nonjudgmental and inclusive health services.

21 January 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
GBGiovanna Nelda Vaccari Bongetta
Giovanna Nelda Vaccari Bongetta
RFRaony Ferreira França
Raony Ferreira França
Maria Olivia Pozzolo PedroMaria Olivia Pozzolo Pedro
Maria Olivia Pozzolo Pedro
KLKae Leopoldo
Kae Leopoldo
Luiza Larrubia Alvares FlorenceLuiza Larrubia Alvares Florence
Luiza Larrubia Alvares Florence
JCJoão Mauricio Castaldelli-Maia
João Mauricio Castaldelli-Maia
Background: E-cigarettes, initially designed for nicotine consumption, are now increasingly being used to smoke cannabis, resulting in a growing trend known as “dual vaping”. This term describes individuals, referred to as “dual users”, who use e-cigarettes for both substances. This study aims to review and analyze existing research on dual vaping, with a focus on the associated health risks and behavioral patterns. Methods: A narrative review of the literature was conducted using PubMed. Studies focusing on individuals who use electronic cigarettes for vaping tobacco and cannabis, either chronically or episodically, were examined. Relevant articles were identified and thematically synthesized to provide a comprehensive overview of the topic. Results: Dual vaping was found to be prevalent among younger men, White and Hispanic populations, and individuals with higher economic status and educational level. The use of one substance was shown to predispose individuals to the use of the other, often leading to concurrent use of both substances. Peer influence and positive expectations regarding e-cigarettes were identified as significant predictors of dual use. Dual vapers exhibited a higher susceptibility to respiratory and systemic symptoms compared to those who exclusively vaped nicotine or cannabis. Moreover, a notable prevalence of psychiatric disorders, such as substance use disorders, anxiety, and depression, was observed in this group. Fruit-flavored e-cigarettes were the most preferred option among dual vapers when using both nicotine and cannabis. Conclusions: Current evidence is insufficient to fully elucidate the long-term impacts of dual vaping on physical and mental health, particularly when compared to individuals who have never vaped. Further studies are needed to gain a more comprehensive understanding of this behavior.

27 July 2023 in International Review of Psychiatry
Verified
Journal Article
Closed access
RFRodrigo Casa Fogo
Rodrigo Casa Fogo
AMAnderson Sousa Martins-Da-Silva
Anderson Sousa Martins-Da-Silva
IBIsrael Kanaan Blaas
Israel Kanaan Blaas
LGLucas Pequeno Galvão
Lucas Pequeno Galvão
EHEllen Hiroe Hasegawa
Ellen Hiroe Hasegawa
JCJoão Mauricio Castaldelli-Maia
João Mauricio Castaldelli-Maia
Given the legislative heterogeneity about involuntary treatment and psychoactive substance users, we opted to perform a systematic review and meta-analysis of the correlates of involuntary substance use disorders (SUD) treatment across different countries. We conducted research on the Pubmed database, searching for involuntary SUD treatment data worldwide. The systematic review analysed a total of 36 articles and included a sample of 47,739 patients. Our review highlights the elevated risk of involuntary treatment among male, unmarried individuals with alcohol and/or opioid use disorders. Targeted preventive and therapeutic interventions should focus on addressing the underlying factors contributing to involuntary treatment, such as psychosis, aggressiveness, suicidal ideation, legal problems, and severe social exposure. By targeting these factors and providing comprehensive care, we can strive to improve outcomes and reduce the burden of substance use disorders in this vulnerable population. It is essential to critically examine and understand the factors contributing to the selection of patients for compulsory treatment. By doing so, we can identify potential gaps or inconsistencies in the current processes and work towards ensuring that decisions regarding compulsory treatment are based on sound clinical and ethical principles.

21 July 2023 in International Review of Psychiatry
Verified
Journal Article
Closed access
MPMayra Cruz Preto
Mayra Cruz Preto
Guilherme KortasGuilherme Kortas
Guilherme Kortas
IBIsrael Kanaan Blaas
Israel Kanaan Blaas
DLDangela Layne Silva Lassi
Dangela Layne Silva Lassi
MCMarcela Waisman Campos
Marcela Waisman Campos
JCJoão Mauricio Castaldelli-Maia
João Mauricio Castaldelli-Maia
Currently, few treatments are available for craving in general, and none of them have received approval for cannabis craving. The objective of this review is to evaluate existing studies analysing treatments for cannabis craving and explore novel treatment possibilities for these patients. The study followed PRISMA guidelines and conducted an extensive database search. Inclusion criteria included human randomised controlled trials examining drug effects on craving symptoms. Exclusion criteria involved studies unrelated to craving, non-pharmacological treatments, duplicates, and non-English/Spanish/Portuguese articles. Our included 22 studies that investigated a wide range of compounds used for cravings related to other drugs, as well as interventions based on healthcare professionals' empirical knowledge. The current pharmacological treatments largely involve off-label drug use and the utilisation of cannabinoid-based medications, such as combinations of THC and lofexidine, oxytocin, progesterone, and N-acetylcysteine. These emerging treatments show promise and have the potential to revolutionise current clinical practices, but further investigation is needed to establish their efficacy. In this context, it is essential to consider non-pharmacological interventions, such as psychotherapy and behavioural treatments. These approaches play a crucial role in complementing pharmacological interventions and addressing the complex nature of the disorder.

5 September 2023 in International Review of Psychiatry
Verified
Journal Article
Closed access
JCJoão Mauricio Castaldelli-Maia
João Mauricio Castaldelli-Maia
VOVictoria Camargos de Oliveira
Victoria Camargos de Oliveira
FIFlávia Mariana Irber
Flávia Mariana Irber
IBIsrael Kanaan Blaas
Israel Kanaan Blaas
BABernard Angerville
Bernard Angerville
GAGisèle Apter
Gisèle Apter
The adverse effects of smoking cessation in individuals with mental health disorders have been a point of concern, and progress in the development of treatment has been slow. The primary first-line treatments for smoking cessation are Nicotine Replacement Therapy, Bupropion, Varenicline, and behavioural support. Nortriptyline and Clonidine are second-line treatments used when the first-line treatments are not effective or are contraindicated. Smoking cessation medications have been shown to be effective in reducing nicotine cravings and withdrawal symptoms and promoting smoking cessation among patients living with mental disorders. However, these medications may have implications for patients’ mental health and need to be monitored closely. The efficacy and side effects of these medications may vary depending on the patient’s psychiatric condition, medication regimen, substance use, or medical comorbidities. The purpose of this review is to synthesise the pharmacokinetics, pharmacodynamics, therapeutic effects, adverse effects, and pharmacological interactions of first- and second-line smoking cessation drugs, with an emphasis on patients suffering from mental illnesses. Careful consideration of the risks and benefits of using smoking cessation medications is necessary, and treatment plans must be tailored to individual patients’ needs. Monitoring symptoms and medication regimens is essential to ensure optimal treatment outcomes.